Literature DB >> 23202739

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.

Claudia Bagni1, Flora Tassone, Giovanni Neri, Randi Hagerman.   

Abstract

Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23202739      PMCID: PMC3533539          DOI: 10.1172/JCI63141

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  127 in total

1.  Fragile X syndrome: is now the time for population screening?

Authors:  Feras M Hantash
Journal:  MLO Med Lab Obs       Date:  2010-05

Review 2.  New perspectives on the biology of fragile X syndrome.

Authors:  Tao Wang; Steven M Bray; Stephen T Warren
Journal:  Curr Opin Genet Dev       Date:  2012-02-28       Impact factor: 5.578

3.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

Authors:  J C Pecknold; D J McClure; L Appeltauer; L Wrzesinski; T Allan
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

4.  Intragenic probe used for diagnostics in fragile X families.

Authors:  A J Verkerk; B B deVries; M F Niermeijer; Y H Fu; D L Nelson; S T Warren; D F Majoor-Krakauer; D J Halley; B A Oostra
Journal:  Am J Med Genet       Date:  1992 Apr 15-May 1

5.  A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.

Authors:  M Giulia Torrioli; Silvia Vernacotola; Laura Peruzzi; Elisabetta Tabolacci; Montserrat Mila; Roberto Militerni; Sebastiano Musumeci; Feliciano J Ramos; Marìa Frontera; Giovanni Sorge; Elisabetta Marzullo; Giusi Romeo; Louis Vallee; Edvige Veneselli; Elena Cocchi; Eleonora Garbarino; Umberto Moscato; Pietro Chiurazzi; Stefania D'Iddio; Menotti Calvani; Giovanni Neri
Journal:  Am J Med Genet A       Date:  2008-04-01       Impact factor: 2.802

6.  Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations.

Authors:  Elisabetta Tabolacci; Umberto Moscato; Francesca Zalfa; Claudia Bagni; Pietro Chiurazzi; Giovanni Neri
Journal:  Eur J Hum Genet       Date:  2008-07-16       Impact factor: 4.246

7.  Cytogenetic findings in moderate and severe mental retardation. A study of an institutionalized population of 1991 patients.

Authors:  J P Fryns; A Kleczkowska; E Kubień; H Van den Berghe
Journal:  Acta Paediatr Scand Suppl       Date:  1984

8.  Deregulation of EIF4E: a novel mechanism for autism.

Authors:  M Neves-Pereira; B Müller; D Massie; J H G Williams; P C M O'Brien; A Hughes; S-B Shen; David St Clair; Z Miedzybrodzka
Journal:  J Med Genet       Date:  2009-06-25       Impact factor: 6.318

9.  AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome.

Authors:  Carolyn M Yrigollen; Blythe Durbin-Johnson; Louise Gane; David L Nelson; Randi Hagerman; Paul J Hagerman; Flora Tassone
Journal:  Genet Med       Date:  2012-04-12       Impact factor: 8.822

10.  The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.

Authors:  Ilaria Napoli; Valentina Mercaldo; Pietro Pilo Boyl; Boris Eleuteri; Francesca Zalfa; Silvia De Rubeis; Daniele Di Marino; Evita Mohr; Marzia Massimi; Mattia Falconi; Walter Witke; Mauro Costa-Mattioli; Nahum Sonenberg; Tilmann Achsel; Claudia Bagni
Journal:  Cell       Date:  2008-09-19       Impact factor: 41.582

View more
  125 in total

Review 1.  Synaptic control of local translation: the plot thickens with new characters.

Authors:  María Gabriela Thomas; Malena Lucía Pascual; Darío Maschi; Luciana Luchelli; Graciela Lidia Boccaccio
Journal:  Cell Mol Life Sci       Date:  2013-11-10       Impact factor: 9.261

2.  Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome.

Authors:  Alicia Mansilla; Antonio Chaves-Sanjuan; Nuria E Campillo; Ourania Semelidou; Loreto Martínez-González; Lourdes Infantes; Juana María González-Rubio; Carmen Gil; Santiago Conde; Efthimios M C Skoulakis; Alberto Ferrús; Ana Martínez; María José Sánchez-Barrena
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-24       Impact factor: 11.205

Review 3.  Autism spectrum disorder-associated genes and the development of dentate granule cells.

Authors:  Hidenori Ito; Rika Morishita; Koh-Ichi Nagata
Journal:  Med Mol Morphol       Date:  2017-05-22       Impact factor: 2.309

4.  mRNA fate: Life and death of the mRNA in the cytoplasm.

Authors:  Michela A Denti; Gabriella Viero; Alessandro Provenzani; Alessandro Quattrone; Paolo Macchi
Journal:  RNA Biol       Date:  2013-03-01       Impact factor: 4.652

5.  Consistency between research and clinical diagnoses of autism among boys and girls with fragile X syndrome.

Authors:  J Klusek; G E Martin; M Losh
Journal:  J Intellect Disabil Res       Date:  2014-02-17

Review 6.  Fragile X syndrome.

Authors:  Wilmar Saldarriaga; Flora Tassone; Laura Yuriko González-Teshima; Jose Vicente Forero-Forero; Sebastián Ayala-Zapata; Randi Hagerman
Journal:  Colomb Med (Cali)       Date:  2014-12-30

7.  Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Authors:  Aimee V Franklin; Margaret K King; Valle Palomo; Ana Martinez; Lori L McMahon; Richard S Jope
Journal:  Biol Psychiatry       Date:  2013-09-13       Impact factor: 13.382

8.  A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.

Authors:  Laura Greiss Hess; Sarah E Fitzpatrick; Danh V Nguyen; Yanjun Chen; Kimberly N Gaul; Andrea Schneider; Kerrie Lemons Chitwood; Marwa Abd Al Azaim Eldeeb; Jonathan Polussa; David Hessl; Susan Rivera; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2016-10       Impact factor: 2.225

9.  Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome.

Authors:  Alexander Pyronneau; Qionger He; Jee-Yeon Hwang; Morgan Porch; Anis Contractor; R Suzanne Zukin
Journal:  Sci Signal       Date:  2017-11-07       Impact factor: 8.192

10.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.